As a result of the OlympiA trial findings, in March of 2022, the United States Food and Drug Administration (FDA) updated the olaparib approval to include the treatment of adult patients with deleterious or suspected deleterious gBRCAm, HER2-negative, high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy [12]. This evidence concerns the gene ERBB2 and breast carcinoma.